May 22, 2006European Journal of Heart Failure
Long-Term Effects of Levosimendan Infusion on Inflammatory Processes and sFas in Patients with Severe Heart Failure
Why the study?
Does a 24-hour levosimendan infusion reduce markers of inflammation and apoptosis in patients with severe heart failure?
Population
34 patients with severe heart failure
Comparison
Levosimendan 24-hour infusion vs Placebo 24-hour infusion
Design
RCT, randomised, double-blind
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Suggests sustained immunomodulatory effects with levosimendan in severe HF; extends evidence beyond acute hemodynamics.
Structured PICO
Does a 24-hour levosimendan infusion reduce markers of inflammation and apoptosis in patients with severe heart failure?
P
Population
34 patients with severe heart failure
I
Intervention
Levosimendan 24-hour infusion
C
Comparator
Placebo 24-hour infusion
O
Outcome
Levels of markers of inflammation and apoptosis (serum IL-6, sFAS, TNF-alpha, sTNF-R1, sTNF-R2) over a period of 30 days following infusionsurrogate
A 24-hour infusion of levosimendan significantly reduces circulating markers of inflammation and apoptosis for up to 30 days in patients with severe heart failure.
Cite This Study
Trikas et al. (2006) studied this question.